Vaxxit

Vaxxit is an Italian biotechnology company dedicated to the development of innovative vaccines and immunotherapies, with a primary focus on HIV/AIDS. The company's core technology is based on the HIV-1 Tat protein, a key regulatory protein produced early after infection that is essential for viral replication and disease progression. Vaxxit's lead candidate is a therapeutic vaccine designed to intensify the effects of antiretroviral therapy (cART) by targeting the Tat protein to restore immune homeostasis. Clinical trials, including Phase 2 studies in Italy and South Africa, have demonstrated the vaccine's ability to reduce the viral reservoir and improve immune function in treated patients. Beyond HIV, the company explores the use of the Tat protein as a molecular transporter or adjuvant for other vaccines and therapeutic applications.